CD226 rs763361 is associated with the susceptibility to type 1 diabetes and greater frequency of GAD65 autoantibody in a brazilian cohort by Mattana, Teresa Cristina Colvara et al.
  Universidade de São Paulo
 
2014
 
CD226 rs763361 is associated with the
susceptibility to type 1 diabetes and greater
frequency of GAD65 autoantibody in a
brazilian cohort
 
 
Mediators of Inammation, New York, v. 2014, Article ID 694948, 7 pages, 2014
http://www.producao.usp.br/handle/BDPI/44881
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Genética e Biologia Evolutiva - IB/BIO Artigos e Materiais de Revistas Científicas - IB/BIO
Research Article
CD226 rs763361 Is Associated with the Susceptibility to
Type 1 Diabetes and Greater Frequency of GAD65 Autoantibody
in a Brazilian Cohort
Teresa Cristina Colvara Mattana,1 Aritania Sousa Santos,1 Rosa Tsuneshiro Fukui,1
Debora Teixeira Oliveira Mainardi-Novo,1 Vinícius Silva Costa,1 Rosa Ferreira Santos,1
Sergio Russo Matioli,2 and Maria Elizabeth Rossi da Silva1
1 Laborato´rio de Carboidratos e Radioimunoensaio (LIM 18), Hospital das Cl´ınicas da Faculdade de Medicina da Universidade de
Sa˜o Paulo, Avenida Dr. Arnaldo 455, 01246-903 Sa˜o Paulo, SP, Brazil
2 Departamento de Gene´tica e Biologia Evolutiva, Instituto de Biocieˆncias da Universidade de Sa˜o Paulo, Rua do Mata˜o 277,
05422-970 Sa˜o Paulo, SP, Brazil
Correspondence should be addressed to Maria Elizabeth Rossi da Silva; mbeth@usp.br
Received 4 February 2014; Revised 10 April 2014; Accepted 10 April 2014; Published 7 May 2014
Academic Editor: Ariadne Malamitsi-Puchner
Copyright © 2014 Teresa Cristina Colvara Mattana et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
CD226 rs763361 variant increases susceptibility to type 1 diabetes (T1D) in Caucasians.There is no data aboutCD226 variants in the
very heterogeneous Brazilian population bearing awide degree of admixture.We investigated its associationwith T1D susceptibility,
clinical phenotypes, and autoimmune manifestations (islet and extrapancreatic autoantibodies). Casuistry. 532 T1D patients and
594 controls in a case-control study. Initially, CD226 coding regions and boundaries were sequenced in a subset of 106 T1D patients
and 102 controls. In a second step, two CD226 variants, rs763361 (exon 7) and rs727088 (3󸀠 UTR region), involved with CD226
regulation, were genotyped in the entire cohort. C-peptide and autoantibody levels were determined. No new polymorphic variant
was found. The variants rs763361 and rs727088 were in strong linkage disequilibrium.The TT genotype of rs763361 was associated
with TID risk (OR = 1.503; 95% CI = 1.135–1.991; 𝑃 = 0.0044), mainly in females (𝑃 = 0.0012), greater frequency of anti-GAD
autoantibody (31.9%× 24.5%; OR = 1.57; CI = 1.136–2.194; 𝑃 = 0.0081), and lower C-peptide levels when compared to those with
TC + CC genotypes (0.41 ± 0.30 ng/dL versus 0.70 ± 0.53 ng/dL 𝑃 = 0.0218). Conclusions. The rs763361 variant of CD226 gene (TT
genotype) was associated with susceptibility to T1D and with the degree of aggressiveness of the disease in T1D patients from Brazil.
Ancestry had no effect.
1. Introduction
Type 1 diabetes is a heterogeneous autoimmune disorder
characterized by severe pancreatic 𝛽-cell loss [1–4]. Discov-
eries of genetic variants associated with risk to T1D have
provided new insights into their functional outcomes and
affected pathways and until now more than 60 loci across
the human genome have been associated with T1D suscepti-
bility (http://www.t1dbase.org).Themajor histocompatibility
complex (MHC) contributes to themain risk, followed by the
insulin and the protein tyrosine phosphatase nonreceptor 22
(PTPN22) genes (2-4), including in the Brazilian population
[5–7]. Nevertheless, established genetic associations explain
only half of the genetic risk of T1D, indicating that other loci
may concur with it.
Genetic and environmental factors contribute to the dif-
ferent incidence of T1D among populations. Indeed, genetic
risk differ among different populations and sometimes even
among groups with the same ethnicity [2, 3]. The Brazilian
population is one of the most heterogeneous in the world
with a wide degree and diverse patterns of admixture. Major
contributions come fromEuropean ancestry (0.771), followed
by African (0.143) and Amerindian ancestries (0.085) [8].
Although the incidence of T1D seems to be increasing in
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Brazil, scarce information is available about genetic and
epidemiological data in this country [9].
Genome-wide association studies (GWAS) identified the
association between the nonsynonymous p.Gly307Ser cod-
ing variant (rs763361) in CD226 gene, located at 18q22.3
and T1D susceptibility in a European population [10]. The
CD226 gene encodes a 67 kDa glycoprotein (336 amino
acids) also known as DNAX accessory molecule-1 (DNAM-
1). CD226 is constitutively expressed in the majority of
CD4+ and CD8+ T lymphocytes, natural killer (NK) cells,
monocytes/macrophages, platelets and megakaryocytes, and
a subset of B lymphocytes, most of which are involved in
immune mechanisms leading to 𝛽-cell destruction [11]. The
poliovirus receptor (CD155) and its family member, nectin 2
(CD112), were identified as the ligands for CD226 [12] and
interaction of CD226 with the ligands inducing NK cell and
CD8+ T cell-mediated cytotoxicity and cytokine secretion
[13].
Recently, Lozano et al. [14] verified that CD226 and
its ligand CD155 were decreased on Th2 polarized na¨ıve T
cells, whereas both were highly expressed under Th17 con-
ditions. CD226 provides a positive costimulatory signal for
T cell proliferation and enhances proinflammatory cytokine
production, thereby shifting the balance between Th1/Th17
and Th2 cells toward a proinflammatory response. Block-
ade of CD226 signaling decreased INF-gamma and IL-17
production. These data suggested that CD226 blockade may
represent an alternative approach for treatment of Th1- and
Th17-driven autoimmune diseases, allowing inhibition of T
cell proliferation and proinflammatory cytokine production
while sparingTh2 response.
Further, a new axis related to human T cell function,
TIGIT/CD226, was described. TIGIT is a T-cell coinhibitory
receptor that binds to CD155 on the dendritic cell surface,
driving them to a more tolerogenic phenotype. Disturbance
in this axis could be expected to contribute to development
of autoimmune diseases [15].
The CD226 rs763361 variant is located in exon 7 encoding
the cytoplasmic tail of CD226 which harbors two phos-
phorylation sites. The substitution from glycine to serine at
residue 307 may affect phosphorylation at residues 322 and
329. Tyrosine phosphorylation at residue 322 of CD226 may
be important for LFA-1 (𝛽2 integrin Lymphocyte Function-
Associated Antigen-1) mediated signaling in T cells. In addi-
tion, serine phosphorylation at residue 329 is also required
for physical association of CD226 with LFA-1 in T cells.
Alternatively, this SNP may alter RNA splicing by disrupting
splice site enhancers or silencers, resulting in an isoform of
CD226 with altered function [16, 17]
Besides TID, the nonsynonymous rs763361 variant has
also been associated with several autoimmune diseases
such as rheumatoid arthritis, celiac disease, Graves’ disease,
systemic lupus erythematosus, multiple sclerosis, systemic
sclerosis, Wegener granulomatosis, and psoriasis mainly in
Caucasian populations [18–21].
Reinforcing the role of CD226 in autoimmune disorders,
a three-variant haplotype in CD226, rs763361-rs34794968-
rs727088, was associated with systemic lupus erythemato-
sus (SLE) and systemic sclerosis-related pulmonary fibrosis.
However, it was proposed that in this context rs727088 could
be the risk SNP interfering on CD226 transcription levels
[22]. Indeed, the association of T1D and the rs763361 variant
in CD226 identified by GWAS could indicate that other
variants might exist and contributed to this risk.
However, there was only a trend of possible association of
rs763361 with SLE in Chinese and with T1D in Colombians
[19] and there is no data about CD226 variants in patients
with T1D in the very heterogeneous Brazilian population.
Therefore, the aim of this study was to investigate the
contribution of CD226 sequence variants to susceptibility to
type 1 diabetes in our population and to correlate risk variants
with clinical data, autoantibody status, C peptide levels, and
HLA (DR) alleles.
We found that rs763361 in CD226 is associated with
type 1 diabetes risk, mainly in females, and with greater
frequency of GAD autoantibody and lower C-peptide levels,
probably reflecting a more aggressive pattern of autoimmune
aggression. We believe that this association in the very het-
erogeneous Brazilian population indicates an even stronger
role for CD226 in susceptibility to T1D.
2. Materials and Methods
2.1. Subjects. 532 T1Dpatients (mean age 23.9±12.8 years, age
at diagnosis 11.6±7.5 years) were recruited fromHospital das
Cl´ınicas da Faculdade de Medicina da Universidade de Sao
Paulo. All patients were diagnosed according to the criteria
established by the American Diabetes Association (ADA) [1]
and treated with two or more doses of insulin per day. The
control group was composed by 592 health volunteers (28 ±
11.5 years) without family history of type 1 or 2 diabetes and
autoimmune diseases and with normal fasting plasmaHbA1c
and glucose levels.
The study design was approved by Institutional Board
Review and all subjects gave written informed consent.
2.2. Blood Parameters. Fasting plasma glucose was deter-
mined using an enzymatic colorimetric assay (LABTEST
GOD-ANA, Brazil). HbA1c was measured using HPLC
(CLAE) and fasting serum C-peptide levels by radioim-
munoassay (HCP-20K, USA); the coefficients of variation
(CV) intra- and inter-assay were, respectively, 4.5%–9.3%.
2.3. Polymerase Chain Reaction (PCR) and Sequencing Anal-
ysis. Genomic DNA was extracted from peripheral blood
leukocytes by the salting-out procedure. The coding region
(exons 2, 3, 4, 5, 6, and part of exon 7) of CD226
(ENSG00000150637) were amplified by polymerase chain
reaction (PCR), using six primers pairs (Invitrogen Life
Technologies, Brazil) in a Veriti Thermal Cycler (Applied
Biosystems, Foster City, CA). PCR primers and conditions
are available on request.
PCR amplified products were submitted to direct
sequencing in an ABI 3130 capillary sequencer (Applied
Biosystem, Foster City,CA) using the BigDye terminator v3.1
cycle sequencing Kit- (Applied Biosystem-Life Technologies)
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and analyzed with the Chromas Lite 2 and Sequencher 4.8
Programs.
2.4. CD226 Genotyping. Two SNPs (rs763361 and rs727088)
were selected as genetic markers on the basis of literature
reports. Genotyping was accomplished in 525 T1D patients
and 592 controls using commercially available genotyping
assays TaqMan (Applied Biosystems Life technologies, USA).
All reactions were carried out using TaqMan Genotyping
MasterMix (Applied Biosystems) on a StepOnePlus real-
time PCR cycler (Applied Biosystems, USA) according to
manufacturer’s instructions. Genotyping was completed in
>99% of the sample and the accuracy was >95%, determined
by direct sequencing of 10% of all samples.
2.5. HLA (DR) Genotyping. HLADRB1 alleles were amplified
by PCR-SSP (Polymerase Chain Reaction-Sequence Specific
Primers) using a generic kit of DRB1 diagnosing typing
(Micro SSPAlleleGenericHLA class IIDNA typing Tray-One-
Lambda INC).
2.6. Autoantibodies. Serum levels of autoantibodies against
glutamic acid decarboxylase and tyrosine phosphatase were
determined by radioimmunoassay (RSR limited, UK; CV <
7%). Normal values (NV) of 700 health controls (considering
3 SD) were >1.0 IU and >0.8 IU for anti-GAD and anti-IA2,
respectively. The sensitivity of both assays is 0.2 IU. Autoan-
tibodies against thyroid peroxidase (Auto Delfia, Turku, Fin-
land, CV = 3.6%–8.2%; NV ≤ 35U/mL), thyroglobulin (Auto
Delfia, Turku, Finland; CV = 2.9%–5.7%; NV ≤ 35U/mL),
and 21-hydroxylase enzyme (RSR limited, UK; CV < 7%; NV
> 1 IU/mL) were determined by radioimmunoassay.
Anti-nuclear (NV < 1/80), anti-liver/kidney microsomal
type 1 antibody, anti-gastric parietal cell, anti-endomysium,
and anti-smooth muscle (NV-negative) were quantified by
indirect immunofluorescence. Rheumatoid factor (RF; NV
< 20 IU/mL) was evaluated using nephelometry and TSH
receptor autoantibody (RSR limited, UK; CV = 6%–10,6%;
NV < 19%) by iodine radioreceptor assay.
2.7. Statistical Analysis. Statistical analyses were performed
using the SPSS 13.0 software for windows. Allelic and geno-
typic association between CD226 polymorphisms and T1D
was carried out using Pearson’s 2 × 2 contingency tables as
implemented in Graph Pad 2.00 software. - Chi-square test
was used to compare qualitative variables and the Fisher exact
test for small samples. Numerical variables with paramet-
ric and nonparametric distributions were compared using
Student’s 𝑡-test and Mann-Whitney test, respectively. In the
case of two samples comparison we used the nonparametric
Wilcoxon test. Results were presented as means and standard
deviations. For the analyses of effects of two independent
variables on a qualitative dependent variable (presence or
absence), we used a nominal logistic fit, available in the JMP
6.03 software (SAS Institute Inc., Cary, NC).
Genotype frequencies were tested for Hardy-Weinberg
equilibrium (HWE) by chi-square test. The recessive model
was used to analyze the genotypes of CD226 allelic variants.
Table 1: Demographic and laboratory characteristics of T1D
patients and controls.
Characteristics T1D Controls 𝑃
Median ± SD
or %
Median ± SD
or %
European ancestry 81.35% 61.75% <0.0001
Gender female 59.4% 38.4% <0.0001
Age (years) 23.92 ± 12.79 27.98 ± 11.56 <0.01
Glucose (mg/dL) 189.24±115.54 83.2 ± 39.3 <0.01
HbA1ca (%) 8.59 ± 2.19 5.32 ± 0.5 <0.01
C peptide (ng/dL) 0.35 ± 0.42 2.00 ± 1.41 <0.0001
HLA DR3 or DR4
alleles 84.2% 39.3% <0.0001
Years of disease 12.2 ± 10.27 — —
Autoantibodies
positivity
Anti-GAD65b 44.25% 1.4% <0.0001
Anti-IA2c 42.4% 1.9% <0.0001
Anti-TPOd 23.8% 12% <0.0001
Anti-Tge 23.6% 7.25% <0.0001
ANAf 21.3% 3.8% <0.0001
TRAbg 7.25% 0.37% <0.0001
Anti-gastric
Parietal cell 6.5% 0.5% <0.0009
Anti-21
hydroxylase 5.3% 0.65% 0.0191
Anti-smooth
muscle 3.5% 0.8% 0.0855
Rheumatoid factor 2.9% 1.0% 0.1801
Anti-LKM-1h 0.6% 0.4% 1.0000
a
HbA1c: Glycated hemoglobin; bAntiGAD65: glutamic acid decarboxylase
antibody; cAnti-IA2: tyrosine phosphatase antibody; dAnti-TPO: anti-
peroxidase antibody; eAnti-Tg: anti-thyroglobulin antibody; fANA: anti-
nuclear antibodies; gTRAb: TSH receptor antibody; hAnti-LKM-1: anti-
liver/kidney microsomal type 1 antibody. 𝑃 values were determined by chi-
square test, Fisher’s exact test, or MannWhitney test, as appropriate. Critical
𝑃 was corrected by Bonferroni method <0.002.
𝑃 ≤ 0.05 was considered statistically significant. For the
analysis of the effects of genetic markers, the critical 𝑃 value
was corrected by Bonferroni adjustments and indicated in
the tables as 𝑃𝑐. Haplotype frequencies and pairwise linkage
disequilibrium between variants were evaluated with the
CubeX software (BGEL/CAiTE, University of Bristol, UK).
Possible haplotypes for each individual were estimated using
the Bayesian method in PHASE v2.1.1.
It was estimated (http://www.lee.dante.br/) that differ-
ences of allelic variant distribution could be detected with a
power exceeding 80% (>95%) at the 0.05 level of significance.
3. Results
3.1. Demographic Features of the Study Subjects. Demo-
graphic and laboratory data of subjects are provided in
Table 1. As expected, HbA1c and glucose levels were higher
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Table 2: Gender effects on frequency of autoantibodies in T1D
patients and controls.
Characteristics T1D
a patients Controls
𝑃
Female Male Female Male
Anti-GAD65b 48.2% 38.0% 0.9% 1.6% 0.82
Anti-IA2c 40.2% 45.6% 1.8% 1.9% 0.66
Anti-TPOd 25.9% 20.2% 19.8% 9.0% <0.005
Anti-Tge 24.5% 23.2% 15.3% 4.0% <0.005
ANAf 22.8% 18.5% 25.0% 3.2% <0.05
TRAbg 5.1% 7.9% 9% 0% <0.05
Anti-gastric parietal cell 9.2% 1.5% 0% 0.4% 0.91
Anti-21 hydroxylase 5.7% 4.8% 0% 1.1% 0.37
Anti-smooth muscle 3.0% 3.1% 1.6% 0.3% 0.35
Rheumatoid factor 3.9% 1.3% 0% 1.1% 0.78
Anti-LKM-1h 0.9% 0% 0% 0.4% 1.00
a
T1D: type 1 diabetes; bAntiGAD65: glutamic acid decarboxylase antibody;
cAnti-IA2: tyrosine phosphatase antibody; dAnti-TPO: anti- peroxidase
antibody; eAnti-Tg: anti-thyroglobulin antibody; fANA: anti-nuclear anti-
bodies; gTRAb: TSH receptor antibody; hAnti-LKM-1: anti- liver/kidney
microsomal type 1 antibody. The Critical 𝑃 values for the lines where the
samples are separated by gender are for gender effect only in a nominal
logistic fit. Critical 𝑃 was corrected by Bonferroni’s criterium <0.0045.
Table 3: Genotype frequencies of CD226 rs763361 and rs727088
variants in patients with T1D and control subjects.
Variant T1D
𝑛 (%)
Control
𝑛 (%) OR CI 𝑃
Genotype
rs763361
TT 178 (33.5) 152 (25.7) 1.453 1.12–1.80 0.0054
TC + CC 353 (66.5) 438 (74.3)
rs727088
CC 166 (31.4) 134 (24.6) 1.410 1.08–1.84 0.0143
CT + TT 362 (68.6) 412 (75.4)
𝑃 values were determined by chi square test; OR: odds ratio; CI: confidence
interval; Critical 𝑃 was corrected by the Bonferroni’s method <0.025.
and C-peptide levels were lower in patients (𝑃 < 0.01). HLA
DR3 or -DR4 alleles prevailed in T1D patients compared to
controls (𝑃 < 0.0001). European ancestry and females were
more frequent in T1D patients as well as several autoanti-
bodies. With the exception of Rheumatoid Factor, anti-21
hydroxilase, anti-liver/kidney microsomal type 1 antibody,
and anti-smooth muscle antibody, all the other autoantibod-
ies were significantly more frequent in T1AD patients than
in the healthy controls (𝑃
𝑐
< 0.003). The greater frequency
of autoantibodies, in patients with T1D, was not related to
gender (Table 2).
3.2. Frequency of Alleles, Genotypes, and Haplotypes
of CD226 Variants in T1D Patients and Controls.
Twelve variants already described in public repositories
(http://www.ensembl.org/) were detected by direct
sequencing: three in exonic regions (rs72481820, rs72481819,
and rs763361) and nine in exon-intron boundaries
(rs75418532, rs57743896, rs1630425, rs73970293, rs77826708,
rs1788101, rs3737395, rs62090790, and rs763362). No new
variant was found.
Genotype frequencies were in Hardy-Weinberg Equi-
librium in all variants for the control population. Allele,
genotype, and estimated haplotype frequencies of variants in
CD226 did not differ between T1D patients (𝑛 = 106) and
controls (𝑛 = 102) (data not shown).
In sequence, two CD226 variants that were previously
related to autoimmune diseases were genotyped in 531 T1D
patients and 590 controls.The rs763361 genotypes were found
to be in HWE in the control group. The TT genotype
prevailed in T1D group (33.5%)when comparedwith controls
(25.7%) (OR = 1.45, 95% CI = 1.12–1.8, 𝑃 = 0.0044) (Table 3).
The second variant tested, rs727088, was found to be in
strong linkage disequilibrium with rs763361 (𝐷󸀠 = −0.948, 𝜒2
= 453.08). The CC genotype was also associated with T1D
patients susceptibility (31.4% versus 24.6%; OR = 1.41; 95%
CI = 1.08–1.84; 𝑃 = 0.0143) but, as the control group was not
inHardy-Weinberg equilibrium (𝑃 = 0.0186), it was excluded
in further analyzes.
3.3. Effects of rs763361 TT Genotype on T1D Characteristics.
The predisposing effect of rs763361 TT genotype to type 1
diabetes was independent of the ancestrality. It prevailed both
in T1D patients of European ancestry (32.5% × 24.2%; OR
= 1.51; 95% CI = 1.09–2.07, 𝑃 = 0.013) as in those of non-
European ancestry (41.2% × 28.0%; OR = 1.8; (95% CI = 1.09–
2.98, 𝑃 = 0.0281) when compared to controls. Compared to
pooled CC+TC genotypes, theCD226 rs763361 TT genotype
had no association with high risk HLA genotypes (DR3 or
DR4), which frequencies were similar between patients with
TT (85.9%) or CT/CC genotypes (82.9%; 𝑃 = 0.42), or with
age at diagnosis (before or after 15-year old), 𝑃 = 0.23.
Patients with new onset diabetes (less than 2 years of
duration) carrying the rs763361 TT genotype also had lower
serum levels of C peptide (0.4 ± 0.3 ng/dL) when compared
with those with TC + CC genotypes (0.7 ± 0.5 ng/dL); 𝑃 =
0.013.
When the frequencies of rs763361 TT genotype in T1D
patients and controls were stratified for gender, the suscep-
tibility risk was observed for T1D females (𝑃 = 0.0012),
but not for males (Table 4).Further, when considering the
entire population (patients with T1D and controls), those
subjects carrying the rs763361 TT genotype had an increased
frequency of anti-GAD65 autoantibody: 31.9%× 24.5%;OR =
1.57; CI = 1.136 − 2.194; and 𝑃 = 0.0081 (Table 5). The mean
titer of anti-GAD65 was higher in females with TT genotypes
(9.8 ± 25.2 IU/mL) than in CC + CT females—at the CD226
rs763361—(4.3±13.7, 𝑃 = 0.0003).The anti-GADmean titers
for TT against CC + CTmales were not significantly different
(2.0 ± 8.2 IU/mL and 1.4 ± 6.0 IU/mL, resp.; 𝑃 = 0.67), also
in the pooled sample.
However, C peptide levels in recent onset patients with
T1D were similar between TT females (0.42 ± 0.28 ng/mL)
and males (0.39 ± 0.33); 𝑃 = 0.79.
In addition, the rs763361 TT genotype of CD226 had no
effect on frequency of extrapancreatic autoantibodies related
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Table 4: Allele and genotype frequencies of CD226 rs763361 variant in patients with type 1 diabetes and controls stratified by gender.
Variant
rs763361 Gender
T1D
𝑛 (%)
Controls
𝑛 (%) OR CI 𝑃
Genotype/allele
TT
Female
111 (35.1) 50 (21.9) 1.928 1.30–2.84 0.0012
TC + CC 205 (64.9) 178 (78.1)
T 360 (57.0) 227 (49.8) 1.335 1.04–1.70 0.0224
C 272 (43.0) 229 (50.2)
TT
Male
67 (31.2) 102 (28.2) 1.154 0.79–1.66 0.504
TC + CC 148 (68.8) 260 (71.8)
T 233 (54.2) 386 (53.3) 1.036 0.81–1.31 0.8213
C 197 (45.8) 338 (46.7)
𝑃 values were determined by chi square test; OR: odds ratio; IC: confidence interval; Critical 𝑃 was corrected by the Bonferroni’s method <0.025.
Table 5: Frequency of autoantibodies in pooled sample of patients
and controls according to gender and CD226 rs763361 genotypes.
Autoantibody Females 𝑃 value Males 𝑃 value
TT CT/CC TT CT/CC
Anti-GADa 35.9 21.7 0.0015 13.6 12.9 0.89
Anti-IA2b 28.8 18.8 0.02 13.1 16.2 0.42
Anti-Gastric Parietal
cell 10.6 3.9 0.53 0.0 1.0 1.00
Anti-smooth muscle 3.9 3.5 1.00 0.9 1.3 1.00
Anti-LKM-1c 0.0 1.3 1.00 0.0 0.5 1.00
Anti-21-hidroxilase 4.8 2.8 0.62 2.3 2.7 1.00
ANAd 24.2 22.1 0.85 9.0 6.1 0.35
Rheumatoid Factor 0.0 6.0 0.08 0.0 1.7 0.58
Anti-TPOe 25.0 22.6 0.66 13.2 11.3 0.61
Anti-Tgf 23.2 18.3 0.36 10.5 8.4 0.56
TRABg 5.9 5.1 1.00 3.2 0.9 0.14
a
AntiGAD65: glutamic acid decarboxylase antibody; bAnti-IA2: tyrosine
phosphatase antibody; cAnti-LKM-1: anti-liver/kidney microsomal type 1
antibody; dANA: anti-nuclear antibody; eAnti-TPO: anti-peroxidase anti-
body; fAnti-Tg: anti-thyroglobulin antibody; gTRAb: TSH receptor anti-
body. 𝑃 values were determined by the Fisher exact test; Critical 𝑃 was
corrected by the Bonferroni’s method <0.0045.
to other autoimmune diseases that usually coexist with T1D
(Table 5).
4. Discussion
In this report we show that rs763361 in exon 7 of CD226 is
associated with type 1 diabetes risk in a Brazilian Cohort (𝑃 =
0.0044). Our results replicate findings of previous European
studies [10, 23] and were independent of ancestry. Despite
of the great admixture of the Brazilian population, the T1D
patients consisted mostly of Caucasians with HLA-DR3 or -
DR4 HLA risk alleles [6]. Including, the direct sequencing of
CD226 coding regions identified twelve variants previously
described in other populations andnonew variantwas found.
New onset T1D patients (with less than two years of
disease duration) bearing the rs763361 TT genotype pre-
sented lower C-peptide levels, indicating accelerated pan-
creatic beta-cell destruction and a more aggressive autoim-
mune phenomenon.Moreover subjects carrying the rs763361
TT genotype had an increased frequency of anti-GAD65
autoantibody. These novel findings might therefore reinforce
CD226’s role in susceptibility to T1D and in disease features.
However, the real effect of this variant is still not com-
pletely understood. The amino acid exchange Gly307Ser
attributed by the rs763361 within the CD226 protein could
alter the two intracytoplasmic phosphorylation sites which
are important in CD226 mediated signaling [16, 17]. As this
protein is involved with cytotoxicity and differentiation of
na¨ıve T CD4+ cells any disturbance in these processes might
contribute to exacerbation of the immune response.However,
Wallace et al. [24] observed that T1D risk correlates with
lower CD226 mRNA, which could reduce cell activation
on cross-linking, altering the interactions of monocytes
with lymphocytes and other immune cells and the CD226
receptors, CD112 and CD155.
The T1D risk associated with rs763361 was more evident
in females than in males, determining increased anti-GAD
titer and frequency, suggesting an additive effect of female
hormones [25]. Gender is associated with differences in
clinical presentation, onset, progression, and outcome of
several autoimmune diseases, and females have stronger
cellular and humoral immune reactions compared with
males [26]. Elevated levels of estrogen and progesterone
are supposed to induce Th2 responses, while low estrogen
and prolactin concentrations have been reported to enhance
Th1 responses. As a matter of fact, clinical evidences show
that menstrual cycle, pregnancy, and menopausal status that
are characterized by fluctuations of endogenous estrogens
significantly influence the course of autoimmune diseases. In
addition, estrogen treatment was found to protect isolated
primary B cells from B cell receptor-mediated apoptosis.
This fact suggested that estrogen could modulate survival
and activation of B cells skewing the na¨ıve immune system
toward autoreactivity and proliferation [25]. C peptide levels
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in recent onset patients with T1D were similar between TT
females (0.42±0.28 ng/mL) andmales (0.39±0.33), 𝑃 = 0.79,
and probably reflect Th1 response.
Although the global incidence of T1D seems not to differ
between male and female, countries with a high incidence
of T1D have a high male to female ratio and those of low
incidence have a low ratio [27]. The increased number of
females in T1D group is consistent with findings of higher
T1D prevalence among females in Brazil [9].
5. Conclusion
We have found that rs763361 in CD226 is associated with
type 1 diabetes risk, greater frequency of GAD autoantibody,
and lower C-peptide levels in a Brazilian cohort, reflecting a
more aggressive pattern of autoimmune disease. We believe
that this association in the very heterogeneous Brazilian
population indicates an even stronger role for CD226 in
susceptibility to T1D. The great risk conferred to female T1D
patients is a recent find and deserves further analyses.
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